Biohaven has launched enrollment for a Phase 2/3 clinical trial of a 75 mg dose of Nurtec ODT (rimegepant) in patients with chronic rhinosinusitis, or long-term inflammation of the nasal cavities and sinuses.
About 200 patients at 25 sites across the U.S. will take part in the study, a randomized, double-blind, placebo-controlled trial scheduled to be completed by February 2023.